LONDON, ONTARIO – January 30, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) a clinical-stage regenerative medicine company, today announced the appointment of Dr. David Lillicrap, M.D., FRCPC to its Scientific Advisory Board (SAB).
Dr. David Lillicrap is Associate Head, Research, and Professor in the Department of Pathology and Molecular Medicine at Queen's University at Kingston, Ontario, Canada. He holds a Tier 1 Canada Research Chair (CRC) in Molecular Hemostasis and is a past Career Investigator of the Heart and Stroke Foundation of Ontario. In 2013, he was elected to the Fellowship of the Royal Society of Canada. Dr. Lillicrap serves as a member of the Medical Advisory Board of the World Federation of Hemophilia. He is a member of the Council of the International Society on Thrombosis and Haemostasis (ISTH), is a past Chair of ISTH’s Scientific and Standardization Committee and is Co-Editor-in-Chief of the Society’s journal, the Journal of Thrombosis and Haemostasis. Dr. Lillicrap has also been a SAB member of the Horizon 2020 HemAcure program developing a personalized medicine approach for treatment of hemophilia of which Sernova is partner. He is an internationally recognized expert on the molecular basis of common inherited bleeding disorders.
“We are pleased to welcome David to Sernova’s Scientific Advisory Board,” said Dr. Philip Toleikis President and CEO Sernova Corp. “Dr. Lillicrap’s internationally recognized leadership in hematology and novel cell and gene therapy-based applications will be instrumental as we expand the breadth and experience of our Scientific Advisory Board in support of Sernova’s hemophilia and other rare disease programs.”
As a Canada Research Chair in Molecular Hemostasis, his program of research focuses on the molecular basis of the hemostatic system (coagulation), with a particular emphasis on the commonest inherited bleeding disorders, hemophilia, and von Willebrand disease. During his tenure as a Canada Research Chair, Dr. Lillicrap’s group has achieved several research accomplishments including the establishment of a national reference laboratory for the genetic diagnosis of inherited bleeding disorders. His research interests focus on three key areas including von Willebrand factor pathobiology, factor VIII immunology and the evaluation of novel gene, and cell-based strategies for the treatment of hemophilia.
The Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the long- term survival and function of immune protected therapeutic cells. The device is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells which then release proteins and hormones as required to treat disease. The device along with therapeutic cells has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans. Within the Horizon 2020 HemAcure program corrected human cells from subjects with Hemophilia A have been shown to engraft within the Cell Pouch, produce Factor VIII and improve blood clotting in a preclinical model of hemophilia A.
For further information contact:
United States: Danny Matthews Solebury Trout Tel: (646) 378-2928 firstname.lastname@example.org www.soleburytrout.com
For investor inquiries and media inquiries in Canada: Dominic Gray Sernova Corp Tel: (519) 858-5126 email@example.com www.sernova.com
Ray Matthews & Associates Tel: (604) 818-7778 firstname.lastname@example.org www.raymatthews.ca
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.